Compare HDFC Pharma And Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.11 | 1.86 |
NAV | ₹16.46 | ₹37.51 |
Fund Started | 14 Sep 2023 | 25 Jun 2018 |
Fund Size | ₹1983.91 Cr | ₹6455.55 Cr |
Exit Load | Exit load of 1%, if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.11
1.86
NAV
₹16.46
₹37.51
Fund Started
14 Sep 2023
25 Jun 2018
Fund Size
₹1983.91 Cr
₹6455.55 Cr
Exit Load
Exit load of 1%, if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
1 Year | 1.47% | -1.54% |
3 Year | - | 25.69% |
5 Year | - | 16.06% |
1 Year
1.47%
-1.54%
3 Year
-
25.69%
5 Year
-
16.06%
Equity | 97.80% | 97.87% |
Cash | 2.20% | 2.13% |
Equity
97.80%
97.87%
Cash
2.20%
2.13%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 10.79% |
Divi's Laboratories Ltd. | 8.35% |
Glenmark Pharmaceuticals Ltd. | 6.45% |
Lupin Ltd. | 6.04% |
Alkem Laboratories Ltd. | 5.78% |
Max Healthcare Institute Ltd. | 5.74% |
Ipca Laboratories Ltd. | 4.56% |
Anthem Biosciences Ltd. | 4.05% |
Torrent Pharmaceuticals Ltd. | 3.89% |
Aster DM Healthcare Ltd. | 3.34% |
Sun Pharmaceutical Industries Ltd. | 12.05% |
Cipla Ltd. | 7.90% |
Dr. Reddy's Laboratories Ltd. | 7.82% |
Divi's Laboratories Ltd. | 7.10% |
Mankind Pharma Ltd. | 6.44% |
Lupin Ltd. | 5.78% |
Aurobindo Pharma Ltd. | 5.19% |
Alkem Laboratories Ltd. | 3.66% |
Cohance Lifesciences Ltd. | 3.01% |
Syngene International Ltd. | 2.98% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 14 Sep 2023 | 25 Jun 2018 |
Description
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
14 Sep 2023
25 Jun 2018